PharmaSphere

PharmaSphere Multiplatform AI Ecosystem, developed by Receptor.AI, is an AI-driven drug discovery platform designed to support discovery teams across the full spectrum of therapeutic modality design — from hit discovery through to lead optimization. The ecosystem is built around three modality-specific platforms — Small Molecules, Peptides, and Proximity Inducers — each powered by tailored Agentic AI that orchestrates modality-specific workflows and AI models. By taking a biology-first, modality-agnostic approach, Receptor.AI delivers objective therapeutic solutions that address structural uncertainty, optimization trade-offs, and complex design challenges.

The multiplatform architecture is modular by design, ensuring focused alignment with the distinct requirements of each drug modality. Each platform provides end-to-end drug candidate design capabilities, enabling teams to pursue diverse therapeutic strategies within a single integrated ecosystem.

Small Molecules Platform

• AI drug discovery workflows tailored for different target classes, including kinases, GPCRs, ion channels, and enzymes.
• AI pocket identification and targeting covering allosteric, hidden, transient, and cryptic binding pockets.
• Automated SAR analysis using a hybrid intelligence approach, combined with AI-driven binding mode identification.
• Multiparametric virtual screening and lead optimization powered by QuorumMap.
• Selectivity optimization against highly similar isoforms and mutants to improve compound specificity.
• Comprehensive ADMET endpoint prediction and optimization through ADMETiQ, covering 80+ endpoints — the largest set available on the platform.
• Design of novel and IP-free compounds to support proprietary drug development programs.

Peptide Platform

• De novo binder design based on endogenous ligands, protein-protein interaction (PPI) partners, or display hits.
• Access to a library of 10,000+ non-canonical amino acids, non-peptide building blocks, and diverse linkage chemistry to enable unlimited structural diversity.
• Multiparametric optimization of peptide activity, membrane permeability, and oral bioavailability.
• A dedicated peptide-to-small-molecule workflow for developing compounds with superior ADMET properties.
• A scaffold-agnostic system that supports peptides of any topology and secondary structure, including targeting of intracellular proteins.

Proximity Inducers Platform (Biologics & Proximity)

• Design of proximity inducers including degraders, molecular glues, and PPI disruptors.
• Antibody-based therapeutics development, encompassing bispecifics, immune cell engagers, and antibody-guided scaffolds.
• Prediction of PPI structures and ternary complexes even in the absence of known structures or homology templates.
• Targeting of both natural and induced PPIs, including transient and membrane-associated interactions.
• Support for diverse therapeutic modalities such as small molecules, peptides, antibody-derived formats, and drug conjugates.

Representative Case Studies and Applications

• Targeting challenging proteins from the integrin family, addressing difficult-to-target binding pockets.
• Designing dual agonists for GPCRs (CD36/GPR120) for treating obesity and inflammation.
• Developing novel approaches to overcome multidrug resistance in Acinetobacter baumannii via ATP synthase targeting.
• In vivo proof-of-concept studies for membrane transporter inhibitors.
• Identification of selective inhibitors for specific ion channel isoforms.

Receptor.AI's PharmaSphere ecosystem is positioned as a comprehensive AI drug discovery partner for life sciences organizations seeking to accelerate and de-risk therapeutic programs across a broad range of modalities and target classes. The platform's modular, agentic architecture enables it to adapt to the specific biological and chemical requirements of each project, supporting both early-stage discovery and advanced lead optimization efforts.